NASDAQ:PRTG - Nasdaq - VGG7185A1369 - Common Stock - Currency: USD
NASDAQ:PRTG (5/20/2025, 8:00:01 PM)
8.33
+0.34 (+4.26%)
The current stock price of PRTG is 8.33 USD. In the past month the price decreased by -15.52%. In the past year, price increased by 58.37%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18 | 327.00B | ||
AMGN | AMGEN INC | 13.25 | 147.86B | ||
GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
NTRA | NATERA INC | N/A | 21.01B | ||
BIIB | BIOGEN INC | 8.25 | 19.13B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B |
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
PORTAGE BIOTECH INC
Clarence Thomas Building, P.O. Box 4649, Road Town
Tortola ONTARIO VG1110 VG
CEO: Ian Walters
Employees: 7
Phone: 4167377600
The current stock price of PRTG is 8.33 USD. The price increased by 4.26% in the last trading session.
The exchange symbol of PORTAGE BIOTECH INC is PRTG and it is listed on the Nasdaq exchange.
PRTG stock is listed on the Nasdaq exchange.
PORTAGE BIOTECH INC (PRTG) has a market capitalization of 13.74M USD. This makes PRTG a Nano Cap stock.
PORTAGE BIOTECH INC (PRTG) currently has 7 employees.
PORTAGE BIOTECH INC (PRTG) has a support level at 7.88 and a resistance level at 8.59. Check the full technical report for a detailed analysis of PRTG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PRTG does not pay a dividend.
PORTAGE BIOTECH INC (PRTG) will report earnings on 2025-08-13, after the market close.
PORTAGE BIOTECH INC (PRTG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-129.8).
The outstanding short interest for PORTAGE BIOTECH INC (PRTG) is 14.3% of its float. Check the ownership tab for more information on the PRTG short interest.
ChartMill assigns a technical rating of 7 / 10 to PRTG. When comparing the yearly performance of all stocks, PRTG is one of the better performing stocks in the market, outperforming 97.17% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to PRTG. The financial health of PRTG is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months PRTG reported a non-GAAP Earnings per Share(EPS) of -129.8. The EPS decreased by -403.1% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -1357.19% | ||
ROE | -2830.59% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to PRTG. The Buy consensus is the average rating of analysts ratings from 6 analysts.